Fig. 2From: Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer typesAnalysis of EBF3 and TBC1D16 methylation in endometrial, prostate and breast cancers. Differentially methylated EBF3 and TBC1D16 CpG sites were analysed in Illumina 450k array DNA methylation data of a Teschendorff et al. dataset (accession number GSE67116 [14]) for endometrial hyperplasia (H, n = 8, in blue), primary endometrial tumours (P, n = 33, in red), lymph node metastases (LN, n = 11, in green), cervical/vaginal metastases (n = 26, magenta), ovarian metastases (n = 5, orange) and abdominal metastases (n = 8, black). b Aryee et al. dataset (accession number GSE38240[15]) for normal prostate (n = 4, blue) and prostate cancer metastases (n = 8, red). c Mathe et al. dataset (accession number GSE78758 [16]) for normal breast (N, n = 4, in blue), primary triple-negative breast cancer tumours (P, n = 23, in red) and lymph node metastases (n = 12, green); *P < 0.05, **P < 0.01Back to article page